Cancer Treatments Carry Serious Cardiovascular Risks

The American Heart Association (AHA) recently issued a scientific statement published in Circulation regarding the high risk of cardiovascular disease faced by many patients with breast cancer. Patients may benefit from a treatment strategy that is informed by weighing the cardiovascular risks compared with the benefits of the drugs.
 
The new statement provides an overview of the known risk factors for heart disease and breast cancer, potential heart damage from breast cancer treatments, and suggestions for mitigating damage.
 
The AHA noted that breast cancer survivors, typically those 65 years and older, are more likely to die from heart disease than breast cancer, which highlights the significance of managing cardiovascular risk factors pre- and post-treatment.
 
“Any patient who is going to undergo breast cancer treatment, whether they have heart disease at the beginning or not, should be aware of the potential effects of the treatments on their heart,” said Laxmi Mehta, MD, chair of the writing group for the statement. “This should not deter or scare patients from undergoing breast cancer treatment but should allow them to make informed decisions with their doctor on the best cancer treatment for them.”
 
During treatment, patients should monitor their overall health, especially their hearts, according to the AHA.
 
The authors said that HER2-targeted breast cancer treatments can cause heart failure. This adverse event can be temporary, and patients may require treatment cessation or additional therapies to improve heart function; however, some patients may experience permanent heart failure, according to the statement.
 
Recent small trials suggest that changing the administration of common chemotherapies may be able to mitigate heart disease risks. For example, when doxorubicin is administered slowly, patients may be at a lower risk of heart failure, the AHA reported.
 
Additionally, dexrazoxane was approved by the FDA to reduce the risk of cell damage among patients with metastatic breast cancer, but further large-scale studies are needed to confirm the impact of the drug.
 
Radiation can also have adverse effects on the heart’s arteries and spark the development of coronary artery disease and blockages, according to the statement. The AHA said that treatment with anthracyclines has been observed to cause abnormal heart rhythms that can be life-threatening in some cases.
 
The authors also said that antimetabolites can cause heart arteries to spasm, which can result in chest pain and heart attacks.
 
Both breast cancer and heart disease share risk factors, including older age, poor diet, family history, lack of exercise, and smoking. The authors suggest that lifestyle modifications could reduce the risk of these conditions, according to the statement.
 
The AHA urges health care providers to monitor patients’ cardiovascular health before, during, and after treatment.
 
“Fortunately, with the advances in breast cancer treatment, there has been a growing number of survivors. However, during and after the treatment of breast cancer, having optimal control of heart disease risk factors is important, because older breast cancer survivors are more likely to die of heart disease than breast cancer,” Dr Mehta said.  


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

The FDA has announced its approval of avatrombopag (Doptelet, AkaRx) tablets to treat low blood platelet count in adults with chronic liver disease (CLD) who are scheduled to undergo a medical or dental procedure.
Officials with the FDA alerted health care professionals about reduced efficacy for some patients taking pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for metastatic urothelial cancer in ongoing clinical trials.
Antibiotic-resistant Acinetobacter baumannii infections put children with compromised immune systems in health care settings at greater risk of infections of the lung, urinary tract, and other sites.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.